We don't care if you are in a big state like California, New York, Florida, or Texas, or one of the smaller states like Wyoming, Montana, or Alaska, if you have proof of off-labeling, we want to talk to you
(PRWEB) June 04, 2014
The Corporate Whistleblower Center says, "It was recently announced a whistleblower will receive over $700,000 for their role in exposing a company that was off-labeling their pharmaceutical product. If you work for a drug maker, and you have very well documented proof the company is involved in off-labeling marketing schemes, we definitely want to talk to you, and we want you to call us at 866-714-6466, so we can carefully explain whistleblower reward programs to you. What makes us unique is as long as your proof is sufficient enough, we will help package all pertinent information and get the whistleblower in contact with some of the nations best whistleblower attorneys.
"We don't care if you are in a big state like California, New York, Florida, or Texas, or one of the smaller states like Wyoming, Montana, or Alaska, if you have proof of off-labeling, we want to talk to you." http://CorporateWhistleblowerCenter.Com
In April of 2014 the Justice Department announced the Pharmaceutical company Astellas Pharma US Inc. will pay $7.3 million to resolve allegations that it violated the False Claims Act in connection with its marketing and promotion of the drug Mycamine for pediatric use.
The settlement resolves allegations that, between 2005 and 2010, Astellas knowingly marketed and promoted the sale of Mycamine for pediatric use, which was not a medically accepted mecication, and therefore, not covered by federal health care programs. During this time period, the FDA approved Mycamine to treat adult patients suffering from serious and invasive infections caused by the fungus Candida, including infections in the esophagus, the blood and the abdomen, and to prevent Candida infections in adults undergoing stem cell transplants. From 2005 through June 2013, however, Mycamine was not approved to treat pediatric patients for any use.
Simple rules for a whistleblower from the Corporate Whistleblower Center:
Do not go to the government first if you are a major whistleblower. The Corporate Whistleblower Center says, “Major whistleblowers frequently go to the federal government thinking they will help. It’s a huge mistake.”
- Do not go to the news media with your whistleblower information. Public revelation of a whistleblower’s information could destroy any prospect for a reward.
- Do not try to force a government contractor, or corporation to come clean to the government about their wrongdoing. The Corporate Whistleblower Center says, “Fraud is so rampant among federal contractors that any suggestion of exposure might result in an instant job termination, or harassment of the whistleblower. Come to us first, tell us what type of information you have, and if we think it’s sufficient, we will help find the right law firms to assist in advancing your information.”
The Corporate Whistleblower Center wants to emphasize there are high quality whistleblowers in every state including California, New York, Florida, Texas,Massachusetts, Maryland, Rhode Island, Virginia, Ohio, Pennsylvania, West Virginia,Tennessee, North Carolina, Georgia, Alabama, Louisiana, Missouri, Michigan, Indiana, Illinois, Wisconsin, Minnesota, Nebraska, Oklahoma, Kansas,Colorado, Utah, Arizona, Nevada, Idaho, Oregon, Washington, and Alaska.
Any type of insider or employee who possesses significant proof of their employer or a government contractor defrauding the federal government is encouraged to contact to Corporate Whistleblower Center anytime at 866-714-6466 or via their web site at http://CorporateWhistleBlowerCenter.Com
For attribution purposes please refer to the April 16th 2014 Justice Department press release: United States Settles False Claims Act Lawsuit Against Astellas Pharma U.S., Inc., U.S. Department of Justice Press Release, April 16, 2014:
The lawsuit is captioned United States ex rel. F.S., et al. v. Astellas Pharma US, Inc., et al., No.10-999